In his first "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with Dr. Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb (BMY) , the drug maker that on Monday announced the $13.1 billion acquisition of MyoKardia to bolster its cardiovascular offerings.
Caforio noted that it's been one year since Bristol acquired Celgene and the combined companies have made "great progress" towards advancing their strategy. MyoKardia's new drug could treat as many as 100,000 patients in the U.S. alone and Caforio said Bristol is the perfect company to take the drug through the regulatory process to bring the drug to market next year.
Bristol Myers remains committed to leading the charge against cardiovascular disease, Caforio said, but also toward rewarding their shareholders. Shares of the company are up 17% over the past year and Caforio added that they continue to have strong financials and are reducing debt as they work towards a balanced capital allocation plan.